Type 1 diabetes could begin in the womb, new research suggests – Diabetologia
Sodium–glucose cotransporter 2 inhibitor‐associated diabetic ketoacidosis in patients with type 1 diabetes: Metabolic imbalance as an underlying mechanism - Ogawa - 2019 - Journal of Diabetes Investigation - Wiley Online Library
Lexicon Fires Back after Sanofi Ends Up-to-$1.7B Diabetes Collaboration
SGLT2 Inhibitors for Teens With Type 1 Diabetes
SGLT2 inhibitors – moving on with the evidence - DiabetesontheNet
Efficacy and safety of sotagliflozin, a dual SGLT1 and SGLT2 inhibitor, as adjunct to insulin in young adults with poorly controlled type 1 diabetes (JDRF Study) - Media Centre | EASD
FDA weighs risks of new treatment for type 1 diabetes - Diabetes Voice
Effects of SGLT2 inhibitors on stroke and its subtypes in patients with type 2 diabetes: a systematic review and meta-analysis | Scientific Reports
How Do SGLT2 (Sodium-Glucose Cotransporter 2) Inhibitors and GLP-1 (Glucagon-Like Peptide-1) Receptor Agonists Reduce Cardiovascular Outcomes? | Arteriosclerosis, Thrombosis, and Vascular Biology
![Sodium-glucose Co-transporter-2 Inhibitors in Type 1 Diabetes—a Dangerous Ally | [current-page:pager]touchENDOCRINOLOGY](https://www.touchendocrinology.com/wp-content/uploads/sites/5/2017/11/table1-minimizing-the-risk-of-diabetic.png "Sodium-glucose Co-transporter-2 Inhibitors in Type 1 Diabetes—a Dangerous Ally | [current-page:pager]touchENDOCRINOLOGY")
Sodium-glucose Co-transporter-2 Inhibitors in Type 1 Diabetes—a Dangerous Ally | [current-page:pager]touchENDOCRINOLOGY
SGLT2 Inhibitors in Type 1 Diabetes: Friend or Foe? - Taking Control Of Your Diabetes®
Orale Begleittherapien bei Typ-1-Diabetes – die Nutzen und Risiken
SGLT-2 Inhibitors in Type 1 Diabetes Mellitus: A Comprehensive Review of the Literature | Bentham Science
FDA says no to Lilly, Boehringer's Jardiance in type 1 diabetes - PMLiVE
Efficacy and safety of the SGLT2 inhibitor dapagliflozin in type 1 diabetes: A meta‑analysis of randomized controlled trials
Non-insulin drugs to treat hyperglycaemia in type 1 diabetes mellitus - The Lancet Diabetes & Endocrinology
The Effects of Empagliflozin, an SGLT2 Inhibitor, on Pancreatic β-Cell Mass and Glucose Homeostasis in Type 1 Diabetes | PLOS ONE
Typ-1-Diabetes
Insulin Therapy in Combination With SGLT2 Inhibitors in Type 1 and Type... | Download Table
EMA hält SGLT2-Inhibitor auch bei Typ-1-Diabetes für geeignet
Hypothesized renal hemodynamic effects of sodium-glucose... | Download Scientific Diagram
![Sodium-glucose Co-transporter-2 Inhibitors in Type 1 Diabetes—a Dangerous Ally | [current-page:pager]touchENDOCRINOLOGY](https://www.touchendocrinology.com/wp-content/uploads/sites/5/2017/11/figure1-potential-mechanisms-for-sodium-glucose.png "Sodium-glucose Co-transporter-2 Inhibitors in Type 1 Diabetes—a Dangerous Ally | [current-page:pager]touchENDOCRINOLOGY")
Sodium-glucose Co-transporter-2 Inhibitors in Type 1 Diabetes—a Dangerous Ally | [current-page:pager]touchENDOCRINOLOGY
Type 1 Diabetes and SGLT2 Inhibitors - Children with Diabetes
Summary of evidence for SGLT-2 inhibitors in type 1 diabetes | Download Table
The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial -
SGLT inhibitors for type 1 diabetes: a finely balanced matter?
SGLT2 inhibitors as adjunctive therapy for type 1 diabetes: balancing benefits and risks - The Lancet Diabetes & Endocrinology
Typ-1-Diabetes
Cureus | Use of Sodium-Glucose Co-Transporter-2 Inhibitors in Type 1 Diabetics: Are the Benefits Worth the Risks?
